Back

Development and validation of the ASGARD-S risk score for optimal timing of echocardiograms in asymptomatic patients with non-severe aortic valve stenosis: the SEAS and SALTIRE II trials

1 September 2024 (09:33 - 09:45)
Organised by: Logo
Congress Presentation Part of: Trial updates and other studies in hypertrophic cardiomyopathy and aortic stenosis Scores ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Edina Hadziselimovic

Bispebjerg University Hospital, Copenhagen (Denmark)

7 More presentations in this session

Presentation thumbnail
Effect of Aficamten on Cardiac Structure and Function in Patients with Obstructive Hypertrophic Cardiomyopathy: The SEQUOIA-HCM CMR Trial
Doctor A. Masri (Portland, US)
Slides Video
Presentation thumbnail
Effect of Aficamten on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy: Results from SEQUOIA-HCM
Doctor J. Spertus (Kansas City, US)
Slides Video
Presentation thumbnail
Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
Doctor S. Hegde (Dallas, US)
Slides Video
Presentation thumbnail
Safety and Outcomes of Standard of Care Medications Withdrawal in Patients with Obstructive Hypertrophic Cardiomyopathy Treated with Aficamten in FOREST-HCM Trial
Doctor A. Masri (Portland, US)
Slides Video
Presentation thumbnail
Aortic valve replacement versus conservative treatment in asymptomatic severe aortic stenosis
Associate Professor M. Banovic (Belgrade, RS)
Slides Video

Access the full session

Session thumbnail
Trial updates and other studies in hypertrophic cardiomyopathy and aortic stenosis
Video

The Event

Event poster

ESC Congress 2024

1 September 2024 09:33 CET
You may be interested in
thumbnail
Congress Presentation
Validation of the developed ASGARD risk score for safe monitoring of asymptomatic patients with non-severe aortic valve stenosis
thumbnail
Congress Presentation
ASGARD risk scores for long-term, individualized cardiovascular surveillance of low-risk patients with asymptomatic non-severe aortic valve stenosis: development and internal validation
thumbnail
Congress Session
Improving risk stratification in aortic stenosis: from the valve to the ventricle

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources